Genflow's gene therapy hits key trial goal in ageing dogs

Health Pharma & Biotech Written by: Ian Lyall 07:29 Tue 08 Sep 2026 --> Proactive has a commercial relationship with Genflow Biosciences Ltd. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Genflow Biosciences Ltd ( LSE:GENF OTCQB:GENFF ) View Price & Profile Genflow's gene therapy hits key trial goal in ageing dogs Published: 07:29 08 Sep 2026 BST Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5) the London-listed biotechnology company developing gene therapies for age-related diseases, announced on Tuesday that its SLAB clinical trial had met its primary endpoint. The trial, known formally as Sarcopenia and Longevity in Aged Beagles, tested the company's SIRT6 centenarian gene therapy in 24 dogs aged over ten. The animals were split into four groups, including two doses of a naked DNA treatment, a single dose of a viral delivery method called AAV8, and a saline control group. Genflow said treated dogs showed a clear improvement in biological age compared with the control group, as measured by a method called the GRIM methylation clock, which estimates biological ageing from chemical changes in DNA. The company said the results build on earlier positive data reported in February and April of this year. Full findings, including muscle tissue analysis, will be presented at the Animal Longevity Summit in Toronto on 1 and 2 October, an event Genflow described as the first conference dedicated solely to ageing research in companion animals. Chief executive Eric Leire said meeting the endpoint was a defining milestone for the company. He said the data provided a foundation for discussions with potential partners in animal health. Genflow said it continues to hold talks with what it called tier one global animal health companies about licensing and commercial deals, without naming any prospective partners. The company's shares trade on the London Stock Exchange and on the OTCQB market in the United States. Genflow's broader pipeline includes a therapy targeting a liver disease called MASH, or metabolic dysfunction-associated steatohepatitis, and an eye treatment aimed at glaucoma and corneal disease. Continue reading